Synopsis: Neuroendocrine tumors (NET) are heterogeneous tumors originating from diverse primary sites. These tumors can produce bioactive amines, peptides, and polypeptides. Increased secretion of serotonin and other bioactive substances results in the classical symptoms of diarrhea and flushing associated with carcinoid syndrome. This ‘Journal Watch’ presents the study, “Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study,” from the Annals Of Oncology, 2017. Authors : M.E. Pavel, E.
Baudin, K.E. Öberg, et al. What was the aim of the study? The study is an update on overall survival (OS) and key safety information of the RADIANT-2 study. The study also aims to explore the predictive and prognostic values of the baseline chromogranin A…
